Stock EVG THERACRYF PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Theracryf Plc

Equities

EVG

GB00BSVYN304

Market Closed - London S.E.
Other stock markets
 11:35:09 2024-05-24 am EDT 		5-day change 1st Jan Change
0.75 GBX 0.00% Intraday chart for Theracryf Plc 0.00% -53.12%
Apr. 26 Evgen Pharma plc will Change its Ticker to TCF from EVG CI
Apr. 26 Evgen Pharma plc will Change its Name to TheraCryf plc CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an enterprise value anticipated at 1.66 times the sales for the current fiscal year, the company turns out to be overvalued.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
THERACRYF PLC Stock Theracryf Plc
-53.12% 4.09M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
B+
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
B+
ARGENX SE Stock argenx SE
-1.69% 21.78B
B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EVG Stock
  4. Ratings Theracryf Plc